Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Differential expression of somatostatin receptors, P44/42 MAPK, and mTOR activation in medulloblastomas and primitive neuroectodermal tumors.

Johnson MD, O'Connell MJ, Silberstein H, Korones D.

Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):532-8. doi: 10.1097/PAI.0b013e3182813724.

PMID:
23455179
2.

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.

Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Góth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB.

Endocr Relat Cancer. 2009 Dec;16(4):1329-38. doi: 10.1677/ERC-09-0101. Epub 2009 Jul 20.

3.

An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET).

Rogers HA, Miller S, Lowe J, Brundler MA, Coyle B, Grundy RG.

Br J Cancer. 2009 Apr 21;100(8):1292-302. doi: 10.1038/sj.bjc.6604979. Epub 2009 Mar 17.

5.

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.

Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM.

Cancer. 2011 Sep 15;117(18):4141-54. doi: 10.1002/cncr.26011. Epub 2011 Mar 8.

6.

Upregulation of SOX2, NOTCH1, and ID1 in supratentorial primitive neuroectodermal tumors: a distinct differentiation pattern from that of medulloblastomas.

Phi JH, Kim JH, Eun KM, Wang KC, Park KH, Choi SA, Kim YY, Park SH, Cho BK, Kim SK.

J Neurosurg Pediatr. 2010 Jun;5(6):608-14. doi: 10.3171/2010.2.PEDS1065.

PMID:
20515335
7.

Insulin-like growth factor I receptor activity in human medulloblastomas.

Del Valle L, Enam S, Lassak A, Wang JY, Croul S, Khalili K, Reiss K.

Clin Cancer Res. 2002 Jun;8(6):1822-30.

9.

Neurotrophin and neurotrophin receptor proteins in medulloblastomas and other primitive neuroectodermal tumors of the pediatric central nervous system.

Washiyama K, Muragaki Y, Rorke LB, Lee VM, Feinstein SC, Radeke MJ, Blumberg D, Kaplan DR, Trojanowski JQ.

Am J Pathol. 1996 Mar;148(3):929-40.

10.

A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes.

Spence T, Perotti C, Sin-Chan P, Picard D, Wu W, Singh A, Anderson C, Blough MD, Cairncross JG, Lafay-Cousin L, Strother D, Hawkins C, Narendran A, Huang A, Chan JA.

Neuro Oncol. 2014 Jan;16(1):62-71. doi: 10.1093/neuonc/not162. Epub 2013 Dec 4.

11.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

12.

Bradykinin-induced p42/p44 MAPK phosphorylation and cell proliferation via Src, EGF receptors, and PI3-K/Akt in vascular smooth muscle cells.

Yang CM, Lin MI, Hsieh HL, Sun CC, Ma YH, Hsiao LD.

J Cell Physiol. 2005 Jun;203(3):538-46.

PMID:
15573401
13.

Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.

Takahashi Y, Kohashi K, Yamada Y, Endo M, Setsu N, Ishii T, Yamamoto H, Iwamoto Y, Oda Y.

Hum Pathol. 2014 May;45(5):984-93. doi: 10.1016/j.humpath.2013.12.012. Epub 2014 Jan 8.

PMID:
24746202
14.

Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.

Blom T, Roselli A, Häyry V, Tynninen O, Wartiovaara K, Korja M, Nordfors K, Haapasalo H, Nupponen NN.

J Neurooncol. 2010 Apr;97(2):217-24. doi: 10.1007/s11060-009-0014-2. Epub 2009 Sep 25.

PMID:
19779861
15.

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.

Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM.

Ann Hematol. 2013 Oct;92(10):1351-8. doi: 10.1007/s00277-013-1770-9. Epub 2013 May 2.

PMID:
23636313
16.

[Hypermethylation as a potential prognostic factor and a clue to a better understanding of the molecular pathogenesis of medulloblastoma--results of a genomewide methylation scan].

Frühwald MC, O'Dorisio MS, Smith L, Dai Z, Wright FA, Paulus W, Jürgens H, Plass C.

Klin Padiatr. 2001 Jul-Aug;213(4):197-203. German.

PMID:
11528554
17.

PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD, Weiss WA, Berger MS, Gupta N, Haas-Kogan DA.

Neuro Oncol. 2012 Sep;14(9):1146-52. doi: 10.1093/neuonc/nos140. Epub 2012 Jun 29.

18.

Sphingosine-1-phosphate induces COX-2 expression via PI3K/Akt and p42/p44 MAPK pathways in rat vascular smooth muscle cells.

Hsieh HL, Wu CB, Sun CC, Liao CH, Lau YT, Yang CM.

J Cell Physiol. 2006 Jun;207(3):757-66.

PMID:
16508949
19.

Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors.

Rostomily RC, Bermingham-McDonogh O, Berger MS, Tapscott SJ, Reh TA, Olson JM.

Cancer Res. 1997 Aug 15;57(16):3526-31.

20.

Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.

El-Habr EA, Levidou G, Trigka EA, Sakalidou J, Piperi C, Chatziandreou I, Spyropoulou A, Soldatos R, Tomara G, Petraki K, Samaras V, Zisakis A, Varsos V, Vrettakos G, Boviatsis E, Patsouris E, Saetta AA, Korkolopoulou P.

Virchows Arch. 2014 Oct;465(4):473-85. doi: 10.1007/s00428-014-1641-3. Epub 2014 Aug 22.

PMID:
25146167
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk